American Conference Institute (ACI) will be holding its 12th Advanced Forum on Biotech Patents on November 30 to December 1, 2010 in Boston, MA. The conference will allow attendees to:
• Adopt a practical approach to incorporate follow-on biologics into your current patent portfolio and brace for the flood of litigation anticipated in the wake of the new legislation;
• Implement strategies to draft and protect diagnostic claims in the wake of Bilski and its progeny;
• Analyze the potential ramifications of Myriad and build fallback positions to protect your claims in light of the attack on the patentability of genes;
• Draft strong claims in compliance with how Courts are applying the standards for written description and enablement set forth in Ariad;
• Incorporate the new PTO initiatives to streamline the patent approval process and anticipate potential challenges during examination;
• Develop global prosecution and litigation strategies to minimize risk and maximize profit in the EU and emerging markets in China and India;
• Assess post-KSR case law developments and tailor your claims to fall within the increasingly strict standards for obviousness;
• Determine standards for materiality and intent to avoid inequitable conduct charges in light of the Therasense decision; and
• Defend and protect IP against third-party infringement.
In particular, ACI's faculty will offer presentations on the following topics:
• Follow-on biologics: Dissecting the legal, scientific and commercial realities of biosimilars and their impact on patent strategies;
• The future of diagnostic method patents: Examining and analyzing the criteria for patentability handed down by the Supreme Court in Bilski -- to be presented in part by Patent Docs author Kevin Noonan;
• Examining the new PTO initiatives: How to benefit from the PTO's initiatives to eliminate backlog -- keynote by Sharon Barner, Deputy Director of the U.S. Patent and Trademark Office;
• Focus on China and India: Breaking Into and securing enforcement of biotechnology IP in burgeoning superpower economies;
• Developing key practice strategies for the European Union;
• Are genes patentable? Examining the potential ramifications of Myriad and developing practical strategies to protect your IP;
• Uncovering potential inventorship issues and resolving ownership uncertainties;
• The art of prior art: Avoiding inequitable conduct claims through proactive drafting and disclosure;
• Navigating the intricacies of PTO patent practice;
• Antibodies: Overcoming patentability hurdles and claim drafting strategies for new technological developments; and
• Overcoming ethical and practical challenges when patenting cutting edge technologies.
An additional master class entitled: "Drafting and Prosecuting Successful Patent Applications in the US and Abroad in an Evolving Biotech Patent Landscape" will be offered from 9:00 am to 12:30 pm on December 2, 2010.
The agenda for the Biotech Patents conference can be found here. A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.
The registration fee ranges from $2,295 (conference) to $2,895 (conference plus master class). Those registering on or before October 29, 2010 will receive a $200 discount. Those interested in registering for the conference can do so here, by calling 1-888-224-2480, or by faxing a registration form to 1-877-927-1563.
Patent Docs is a sponsor and media partner of ACI's Biotech Patents conference.
Comments